ANIK vs BVS
ANIK: Anika Therapeutics manufactures and markets hyaluronic acid (HA)-based medical products for orthopedic pain management, tissue regeneration, and non-orthopedic surgical applications. BVS: Bioventus is an orthopedic medical technology company focused on pain relief and musculoskeletal treatment through hyaluronic acid viscosupplements, bone growth stimulators, and emerging surgical and regenerative medicine platforms.
Side-by-side fundamentals
| Metric | ANIK | BVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.01 | $11.63 | |
| Market cap as of 2026-07-23 | $199M | $972M | |
| P/E as of 2026-07-23 | n/a | 34.11 | |
| PEG as of 2026-07-23 | n/a | 2.25 | |
| Net margin as of 2026-07-23 | -9.5% | +4.9% | BVS higher |
| Gross margin as of 2026-07-23 | +58.6% | +68.7% | BVS higher |
| Operating margin as of 2026-07-23 | -10.5% | +9.9% | BVS higher |
| ROE as of 2026-07-23 | -7.7% | +16.3% | BVS higher |
| ROA as of 2026-07-23 | -5.9% | +4.2% | BVS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.49 | ANIK lower |
| Revenue growth (YoY) as of 2026-07-23 | -15.4% | +1.5% | BVS higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +3.5% | BVS higher |
| Beta as of 2026-07-23 | 0.22 | 0.70 | |
| 1-year return as of 2026-07-22 close | +41.8% | +88.6% | BVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.